Bloedbiomarkers voor de ziekte van Alzheimer: de klinische waarde op de geheugenpoli
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
BACKGROUND: The development of highly sensitive assays has enabled the detection of biomarkers of Alzheimer's disease in blood. In this literature review, we discuss their clinical applicability based on recent studies. METHODS: A systematic search was conducted across Embase, Pubmed, Web of Science, Cochrane Central, and Google Scholar for studies published since 2021, using the search terms 'Alzheimer's Disease', 'Blood Biomarkers' and 'Memory Clinic'. RESULTS: Based on the 11 included studies, pTau181, pTau217, NfL and GFAP appear to be clinically relevant (diagnostic value, AUC > 0.7) as blood biomarker. CONCLUSIONS: Multiple blood biomarkers appear to be clinically relevant for diagnostics in a memory clinic setting. However, this conclusion is based on just 11 studies, highlighting the need for further research in real-world populations within memory clinics.
Fields of Study & Subjects
Dementia and Cognitive Impairment Research
Alzheimer's disease research and treatments
Cerebrospinal fluid and hydrocephalus
Publication details
- Journal / source
- Tijdschrift voor Gerontologie en Geriatrie
- Volume
- 57
- Issue
- 1
- Pages
- 18–18
- Publication date
- 31 March 2026
- Language
- NL